Medical Patent Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Colorectal
Studies from University of Melbourne, Department of Surgery describe new findings in colorectal
January 25th, 2008
Investigators publish new data in the report 'Alterations in vascular architecture and permeability following OXi4503 treatment.' "OXi4503 retards tumor growth in a dose-dependent manner and improves survival in a murine model of colorectal liver metastases. This agent causes extensive vascular shutdown by selectively altering the tubulin cytoskeleton within the endothelial cells of tumor vessels," investigators in Heidelberg, Australia report. "The destruction of tumor vessels is incomplete, however, and tumor revascularization occurs after the treatment. This study evaluates the pattern of microcirculatory changes and alterations to the ultrastructural properties of...
Source: Medical Patent Business Week (2008-01-25)
|
